DrugPatentWatch Database Preview
Drugs in Development Information for MN-166
Try a free trial
See Plans and Pricing
Summary for MN-166
| US Patents | 694 |
| International Patents | 6,885 |
| US Patent Applications | 1,596 |
| WIPO Patent Applications | 878 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 1 (2019-10-01) |
| Vendors | 79 |
US Patents for MN-166
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MN-166 | ➤ Sign Up | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ➤ Sign Up |
| MN-166 | ➤ Sign Up | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | ➤ Sign Up |
| MN-166 | ➤ Sign Up | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | ➤ Sign Up |
| MN-166 | ➤ Sign Up | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag | The Catholic University of America (Washington, DC) | ➤ Sign Up |
| MN-166 | ➤ Sign Up | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | ➤ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MN-166
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MN-166 | Canada | 2961033 | 2034-09-11 | ➤ Sign Up |
| MN-166 | European Patent Office | 3192791 | 2034-09-11 | ➤ Sign Up |
| MN-166 | Japan | WO2016039408 | 2034-09-11 | ➤ Sign Up |
| MN-166 | World Intellectual Property Organization (WIPO) | 2016039408 | 2034-09-11 | ➤ Sign Up |
| MN-166 | Australia | 2012222348 | 2031-03-01 | ➤ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
